Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study.

IF 5.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

World Journal of Diabetes Pub Date : 2025-11-15 DOI:10.4239/wjd.v16.i11.112999

Sameer Kassem, Buthaina Khalaila, Nili Stein, Adnan Zaina

{"title":"Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study.","authors":"Sameer Kassem, Buthaina Khalaila, Nili Stein, Adnan Zaina","doi":"10.4239/wjd.v16.i11.112999","DOIUrl":null,"url":null,"abstract":"Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play a key role in managing type 2 diabetes mellitus (T2DM). Transitioning between different GLP-1RA has been proposed as a treatment strategy.Aim: To investigate switching patterns between GLP-1RA and their impact on glycemic control.Methods: A retrospective study involving patients with T2DM who initiated GLP-1RA therapy between 2009 and 2021 and transitioned to another GLP-1RA. Baseline glycated hemoglobin (HbA1c) was defined as the most recent measurement within 1 year prior to switching, and follow-up HbA1c was the first measurement recorded 4-15 months post-switch.Results: Among 70654 patients initiating GLP-1RA therapy, 18047 (25.5%) switched regimens. In the 13970 patients with available HbA1c, levels decreased from 8.5% ± 1.6% to 7.6% ± 1.4% (P < 0.001). HbA1c decreased in 78.3% (10943/13970) of these patients, with the most frequent improvement observed in those switching from daily to weekly GLP-1RA (81%, 5582/6890).Conclusion: Switching between GLP-1RAs can serve as a practical alternative to treatment intensification for effectively managing T2DM.","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 11","pages":"112999"},"PeriodicalIF":5.1000,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12635781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v16.i11.112999","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play a key role in managing type 2 diabetes mellitus (T2DM). Transitioning between different GLP-1RA has been proposed as a treatment strategy.

Aim: To investigate switching patterns between GLP-1RA and their impact on glycemic control.

Methods: A retrospective study involving patients with T2DM who initiated GLP-1RA therapy between 2009 and 2021 and transitioned to another GLP-1RA. Baseline glycated hemoglobin (HbA_1c) was defined as the most recent measurement within 1 year prior to switching, and follow-up HbA_1c was the first measurement recorded 4-15 months post-switch.

Results: Among 70654 patients initiating GLP-1RA therapy, 18047 (25.5%) switched regimens. In the 13970 patients with available HbA_1c, levels decreased from 8.5% ± 1.6% to 7.6% ± 1.4% (P < 0.001). HbA_1c decreased in 78.3% (10943/13970) of these patients, with the most frequent improvement observed in those switching from daily to weekly GLP-1RA (81%, 5582/6890).

Conclusion: Switching between GLP-1RAs can serve as a practical alternative to treatment intensification for effectively managing T2DM.

查看原文本刊更多论文

胰高血糖素样肽1受体激动剂在2型糖尿病中的转换模式：一项回顾性现实世界研究。

背景：胰高血糖素样肽-1受体激动剂（GLP-1RAs）在治疗2型糖尿病（T2DM）中发挥关键作用。不同GLP-1RA之间的过渡已被提出作为一种治疗策略。目的：探讨GLP-1RA之间的转换模式及其对血糖控制的影响。方法：一项回顾性研究，涉及2009年至2021年间开始GLP-1RA治疗并过渡到另一种GLP-1RA治疗的T2DM患者。基线糖化血红蛋白（HbA1c）定义为转换前1年内的最新测量值，随访HbA1c是转换后4-15个月记录的首次测量值。结果：在70654例开始GLP-1RA治疗的患者中，18047例（25.5%）切换了治疗方案。在13970例可用HbA1c患者中，HbA1c水平从8.5%±1.6%降至7.6%±1.4% （P < 0.001）。78.3%（10943/13970）的患者HbA1c下降，从每日GLP-1RA转为每周GLP-1RA的患者改善最常见（81%,5582/6890）。结论：在GLP-1RAs之间切换可以作为有效管理T2DM的强化治疗的实用替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

自引率

2.40%

发文量

909

期刊介绍： The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.